Glenmark Pharmaceuticals launches generic version of diuretic Bumetanide injection

The launch affirms commitment to Glenmark's continued focus on institutional business, company Senior Vice President, Business Development Portfolio, Product Launch& Strategy, Vijay Raghavan said. The Bumex injection, 0.25 mg/mL achieved annual sales of approximately USD 16.5 million, the company said citing IQVIA sales data for the 12-month period ended November 2022.
Source: The Economic Times Healthcare and Biotech News - Category: Pharmaceuticals Source Type: news